Previous close | 1.9000 |
Open | 1.9000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 20.00 |
Expiry date | 2024-06-21 |
Day's range | 1.9000 - 1.9000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Besides Wall Street's top -and-bottom-line estimates for Guardant Health (GH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
PALO ALTO, Calif., April 22, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s Shield™ blood test for colorectal cancer (CRC) screening on Thursday, May 23, 2024.